News & Updates

The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.

New drug applications approved by US FDA as of 16-31 July 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Treatment with JNJ-77242113, an oral interleukin-23 receptor (IL-23R) antagonist peptide, leads to significant improvement in skin lesions, as measured by the Psoriasis Area and Severity Index (PASI) scores, in patients with moderate-to-severe plaque psoriasis, according to the FRONTIER 1 study presented at WCD 2023.

Treatment with nemolizumab significantly improves itch and skin clearance in patients with prurigo nodularis compared with placebo, according to the phase III OLYMPIA 2 trial presented at WCD 2023.

In patients with cutaneous squamous cell carcinoma (cSCC) presenting with satellitosis or in-transit metastasis (S-ITM), the size and the number of S-ITM lesions are associated with a higher risk of relapse, while the number of S-ITM confers an increased risk of specific death, reveals a study.

A new lotion formulation of 20% oxybutynin hydrochloride (20% OL) demonstrates efficacy in reducing palmar sweat volume among patients with primary palmar hyperhidrosis (PPHH) when compared with placebo, results of a phase III study have shown.

Treatment of Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer with high mortality and rising incidence, at either an academic or a high-volume centre tends to lead to better patient survival, as shown in a recent study.